Abbott Laboratories $ABT Shares Sold by Reynders McVeigh Capital Management LLC

Posted by on Sep 15th, 2026

Reynders McVeigh Capital Management LLC reduced its holdings in Abbott Laboratories (NYSE:ABT – Free Report) by 1.5% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 415,235 shares of the healthcare product maker’s stock after selling 6,426 shares during the period. Abbott Laboratories makes up approximately 1.5% of Reynders McVeigh Capital Management LLC’s holdings, making the stock its 22nd largest holding. Reynders McVeigh Capital Management LLC’s holdings in Abbott Laboratories were worth $37,678,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. BlackRock Inc. lifted its stake in Abbott Laboratories by 4.6% in the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after purchasing an additional 6,769,518 shares in the last quarter. State Street Corp grew its position in shares of Abbott Laboratories by 2.1% in the fourth quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker’s stock valued at $10,004,880,000 after purchasing an additional 1,627,791 shares in the last quarter. Capital International Investors increased its holdings in shares of Abbott Laboratories by 2.6% in the fourth quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker’s stock valued at $7,922,519,000 after purchasing an additional 1,614,706 shares during the last quarter. J. Stern & Co. LLP increased its holdings in shares of Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after purchasing an additional 39,005,451 shares during the last quarter. Finally, Capital Research Global Investors lifted its position in Abbott Laboratories by 1.0% during the fourth quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker’s stock worth $4,907,523,000 after buying an additional 400,400 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

  • Positive Sentiment: The agreement resolves the U.S. Department of Justice investigation, related civil claims, and lawsuits brought by certain states and relators. Abbott said the settlement includes no admission of fault or liability, while the government’s criminal investigation has been closed. Abbott Department of Justice settlement announcement
  • Positive Sentiment: Abbott stated that government testing of unopened formula from affected infants’ homes was negative for Cronobacter sakazakii, and that no unopened, distributed Abbott formula has ever tested positive for the bacteria. These points may limit some ongoing product-liability concerns. NBC News report on Abbott formula settlement
  • Neutral Sentiment: Abbott had recently gained as the broader healthcare sector advanced and after six consecutive losing sessions, suggesting some of the current move reflects market and sector trading rather than company-specific fundamentals alone. Abbott market performance report
  • Negative Sentiment: The settlement requires Abbott to pay more than $384 million to resolve allegations that it produced infant formula in potentially contaminated conditions at its Michigan and Arizona facilities, failed to conduct adequate testing, and did not disclose positive contamination tests to regulators. The cash cost and renewed scrutiny of manufacturing controls are weighing on sentiment. Inside Monkey report on Abbott infant-formula legal risks
  • Negative Sentiment: The matter relates to the closure of Abbott’s Sturgis, Michigan, facility and the 2022 recall, keeping attention focused on reputational damage, regulatory oversight, and potential disruption in the infant-formula business. RTT News report on Abbott settlement

Wall Street Analyst Weigh In

Several analysts have issued reports on ABT shares. Bank of America dropped their target price on Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Wells Fargo & Company boosted their price target on shares of Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Weiss Ratings raised shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 6th. TD Cowen restated a “buy” rating and set a $135.00 price objective on shares of Abbott Laboratories in a research report on Tuesday, September 8th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and set a $130.00 target price on shares of Abbott Laboratories in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $119.50.

View Our Latest Research Report on Abbott Laboratories

Abbott Laboratories Trading Down 1.1%

ABT stock traded down $1.10 during midday trading on Tuesday, hitting $101.99. 7,418,005 shares of the company’s stock were exchanged, compared to its average volume of 11,513,019. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $176.48 billion, a PE ratio of 33.01, a P/E/G ratio of 1.89 and a beta of 0.59. The business has a 50-day simple moving average of $105.75 and a two-hundred day simple moving average of $99.66.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The company’s quarterly revenue was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, sell-side analysts predict that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Profile

(Free Report)

Abbott Laboratories (NYSE: ABT) is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company’s medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.

Featured Articles

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.